ClinicalTrials.gg
CompletedNCT01427933Updated Feb 6, 2017Results posted

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

A Phase 2 interventional study of Ramucirumab (IMC-1121B) and Eribulin in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 52 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-06.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.

Enrollment
40th of 80
141 · median 138
Started
2011
with 2 others
Phase 2
41 of 88
2 open now
Registered
43rd of 88
by date

Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 40th largest by enrollment of the 80 interventional ones that give a count, is one of 3 that started in 2011, is one of 41 in phase 2, and was the 43rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Breast Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have or cytologically confirmed invasive breast cancer which at the time of study entry is either locally recurrent disease not amenable to curative therapy or Stage IV disease (American Joint Committee on Cancer Staging Criteria for breast cancer)
  • Have measurable and/or nonmeasurable disease per version 1.1 (RECIST v1.1)
  • Have received at least 2 but not more than 4 prior cytotoxic chemotherapy regimens in the locally recurrent or setting
  • Have received prior treatment with both anthracyclines and taxanes, either in the metastatic, or neoadjuvant setting
  • Have received Human Epidermal Growth Factor Receptor 2 () directed treatment; or are not a candidate for HER-2-directed treatment if the patient has HER-2 positive disease
  • Have completed any prior radiotherapy and/or hormonal therapy at least 1 week prior to randomization and have recovered from all treatment-related toxicities
  • Have an (ECOG) Performance Status of 0 or 1
  • Have within normal limits
  • Have discontinued all previous chemotherapy treatments for cancer at least 3 weeks prior to randomization and recovered from clinically significant toxic effects
  • Have resolution to Grade less than or equal to 1 [by the National Cancer Institute (NCI-CTCAE), Version 4.0] of all clinically significant toxicities of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy, which must have resolved to Grade less than or equal to 2
  • Have adequate hematologic, hepatic, renal, and coagulation function
  • Test negative for pregnancy
  • Have a of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Have a concurrent active other other than adequately treated non-melanomatous skin cancer or other noninvasive or in situ neoplasms
  • Are currently enrolled in, or recently discontinued from, a clinical trial involving an product, or concurrently enrolled in any other type of medical research judged not to be medically compatible with the study
  • Have received investigational therapy within 3 weeks prior to randomization
  • Have received prior ramucirumab or eribulin
  • Have a known sensitivity to agents of similar biologic composition as ramucirumab, halichondrin B and/or halichondrin B chemical derivative
  • Have received bevacizumab within 6 weeks prior to randomization
  • Have uncontrolled or poorly controlled hypertension
  • Have congenital prolonged syndrome (or have a family history) or prolongation of QTc at baseline
  • Have a history of additional risk factors for torsades de pointes within the last year prior to randomization
  • Have an implantable pacemaker or automatic implantable cardioverter defibrillator
  • Have bradycardia
  • Have an acute/subacute bowel obstruction or history of chronic diarrhea requiring ongoing medical intervention within 6 months prior to randomization
  • Have a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
  • Have experienced a Grade 3 or greater bleeding event within 3 months prior to randomization
  • Have experienced any Grade 3 or greater arterial thromboembolic events within 6 months prior to randomization, or venous thromboembolic event within 3 months prior to randomization
  • Have undergone major surgery within 4 weeks prior to randomization or subcutaneous venous access device placement within 7 days prior to randomization
  • Have a planned major surgery to be performed during the course of the trial
  • Have uncontrolled metabolic conditions
  • Have an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy
  • Have known (HIV) infection or acquired immunodeficiency syndrome (AIDS)
  • Have pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment including the use of oxygen
  • Have received a prior allogeneic organ or tissue transplantation
  • Have had a serious nonhealing wound, ulcer, or bone fracture within 4 weeks prior to randomization
  • Have known
  • Have cirrhosis ( Level B or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or ascites
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Ramucirumab and Eribulin

    Ramucirumab 10 milligrams/kilogram (mg/kg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle Eribulin 1.4 milligrams/square meter (mg/m²) administered by IV bolus on Day 1 and Day 8 of each 3-week cycle

    Biological: Ramucirumab (IMC-1121B) · Drug: Eribulin

  • Active comparator
    Eribulin Monotherapy

    Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle

    Drug: Eribulin

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as time from date of randomization until the date of objectively determined progression defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria or death from any cause, whichever is first. Progressive disease (PD) defined as ≥20% increase in sum of diameter (SOD) of target lesion with the sum demonstrating an increase of ≥5 mm; appearance of ≥1 new lesions or unequivocal progression of non-target lesions. Participants with no baseline disease assessment were censored at randomization date, regardless of whether or not objectively determined PD or death was observed; participants not known to have died or to have objective progression as of data inclusion cutoff date were censored at last post baseline radiological assessment date or randomization date, if there was no post baseline radiological assessment.

    Time frame: Start of treatment until documented disease progression or death from any cause up to 16.5 months

Secondary outcomes

  1. Overall Survival (OS) Randomization to Date of Death From Any Cause

    Time from the date of randomization to the date of death from any cause. For participants who were not known to have died as of the data-inclusion cut-off date, OS data were censored on the last date the participants were known to be alive prior to that cut-off date.

    Time frame: Randomization to date of death from any cause up to 28.6 months

  2. Objective Response Rate (ORR) Percentage of Participants With Measurable Disease Achieving a Best Overall Response of Partial Response (PR) or Complete Response (CR)

    ORR was defined as the percentage of participants with measurable disease achieving a best overall response of PR or CR as defined by RECIST v.1.1. CR defined as disappearance of all lesions and pathological lymph nodes reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in SOD of target lesions. Participants who did not have any post baseline tumor response assessments for any reason were considered non-responders and included in the denominator when calculating the response rate. ORR for each treatment arm calculated as: \[(CR + PR in the treatment arm) divided by (total number of participants in the treatment arm)\] x 100.

    Time frame: Start of treatment until documented CR or PR up to 16.5 months

  3. Duration of Response (DOR) Time of Response to Progressive Disease

    DOR was measured from the time criteria were met for first objectively recorded CR or PR until first date criteria for PD was met or death. Response defined using RECIST v1.1 criteria. CR defined as disappearance of all lesions and pathological lymph nodes reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in sum of diameter (SOD) of target lesions. PD defined ≥20% increase in SOD of target lesion with the sum demonstrating an increase of ≥5 mm; appearance of ≥1 new lesions or unequivocal progression of non-target lesions. Participants who were not known to have died and who did not have PD were censored at the date of the last tumor assessment prior to the date of any subsequent systemic anticancer therapy.

    Time frame: Time from Observed CR or PR to PD up to 12.1 months

  4. Change in Tumor Size (CTS)

    CTS was defines as the change from baseline measurement of target lesions to the post treatment measurement in participants with measurable disease. Change was assessed using radiographic imagining. Log ratio calculated as: log of (tumor size post baseline) divided by (tumor size at baseline). A negative result indicated a shrinking tumor.

    Time frame: Baseline, 6 weeks

  5. Number of Participants With Anti-Ramucirumab Antibodies

    The number of participants who developed treatment-emergent antibody responses after baseline. The antibody test can produce positive results in participants without ramucirumab exposure. Treatment emergent anti-ramucirumab antibody positive was defined as: when baseline titer was greater than 0 and post baseline titer was equal to or greater than 4-fold the baseline titer or if the baseline titer was not detected and post baseline titer is equal to or greater than a value of 20.

    Time frame: Day 1 of Cycle 1, Cycle 3, Cycle 5 and 30 days after last dose of study drug up to 17.7 months

Other outcomes

  1. Number of Participants With Adverse Events (AE) and Participants Who Died

    Participants who died or who had clinically significant events defined as serious AEs (SAEs) and other non-serious AEs (regardless of causality). A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline up to end of treatment and within 30 days of last dose of study drug (22.6 months)

07

Results

Posted Aug 19, 2014

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab and EribulinEribulin Monotherapy
Started7170
Received at least 1 dose of study drug6965
Completed6357
Not completed813
Withdrew: Withdrawal by subject58
Withdrew: Lost to follow-up15
Withdrew: Other10
Withdrew: Investigator's decision10

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as time from date of randomization until the date of objectively determined progression defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria or death from any cause, whichever is first. Progressive disease (PD) defined as ≥20% increase in sum of diameter (SOD) of target lesion with the sum demonstrating an increase of ≥5 mm; appearance of ≥1 new lesions or unequivocal progression of non-target lesions. Participants with no baseline disease assessment were censored at randomization date, regardless of whether or not objectively determined PD or death was observed; participants not known to have died or to have objective progression as of data inclusion cutoff date were censored at last post baseline radiological assessment date or randomization date, if there was no post baseline radiological assessment.

Time frame:
Start of treatment until documented disease progression or death from any cause up to 16.5 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsRamucirumab and EribulinEribulin Monotherapy
Progression-Free Survival (PFS)4.4 (3.1 to 6.7)4.1 (3.2 to 5.6)
SecondaryOverall Survival (OS) Randomization to Date of Death From Any Cause

Time from the date of randomization to the date of death from any cause. For participants who were not known to have died as of the data-inclusion cut-off date, OS data were censored on the last date the participants were known to be alive prior to that cut-off date.

Time frame:
Randomization to date of death from any cause up to 28.6 months
Reported as:
Median · Months
Overall Survival (OS) Randomization to Date of Death From Any Cause
MonthsRamucirumab and EribulinEribulin Monotherapy
Overall Survival (OS) Randomization to Date of Death From Any Cause13.5 (10.4 to 17.9)11.5 (9.0 to 17.3)
SecondaryObjective Response Rate (ORR) Percentage of Participants With Measurable Disease Achieving a Best Overall Response of Partial Response (PR) or Complete Response (CR)

ORR was defined as the percentage of participants with measurable disease achieving a best overall response of PR or CR as defined by RECIST v.1.1. CR defined as disappearance of all lesions and pathological lymph nodes reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in SOD of target lesions. Participants who did not have any post baseline tumor response assessments for any reason were considered non-responders and included in the denominator when calculating the response rate. ORR for each treatment arm calculated as: \[(CR + PR in the treatment arm) divided by (total number of participants in the treatment arm)\] x 100.

Time frame:
Start of treatment until documented CR or PR up to 16.5 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Percentage of Participants With Measurable Disease Achieving a Best Overall Response of Partial Response (PR) or Complete Response (CR)
percentage of participantsRamucirumab and EribulinEribulin Monotherapy
Objective Response Rate (ORR) Percentage of Participants With Measurable Disease Achieving a Best Overall Response of Partial Response (PR) or Complete Response (CR)19.7 (11.2 to 30.9)24.3 (14.8 to 36.0)
SecondaryDuration of Response (DOR) Time of Response to Progressive Disease

DOR was measured from the time criteria were met for first objectively recorded CR or PR until first date criteria for PD was met or death. Response defined using RECIST v1.1 criteria. CR defined as disappearance of all lesions and pathological lymph nodes reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in sum of diameter (SOD) of target lesions. PD defined ≥20% increase in SOD of target lesion with the sum demonstrating an increase of ≥5 mm; appearance of ≥1 new lesions or unequivocal progression of non-target lesions. Participants who were not known to have died and who did not have PD were censored at the date of the last tumor assessment prior to the date of any subsequent systemic anticancer therapy.

Time frame:
Time from Observed CR or PR to PD up to 12.1 months
Reported as:
Median · months
Duration of Response (DOR) Time of Response to Progressive Disease
monthsRamucirumab and EribulinEribulin Monotherapy
Duration of Response (DOR) Time of Response to Progressive Disease5.5 (3.1 to 7.1)3.0 (1.4 to 4.4)
SecondaryChange in Tumor Size (CTS)

CTS was defines as the change from baseline measurement of target lesions to the post treatment measurement in participants with measurable disease. Change was assessed using radiographic imagining. Log ratio calculated as: log of (tumor size post baseline) divided by (tumor size at baseline). A negative result indicated a shrinking tumor.

Time frame:
Baseline, 6 weeks
Reported as:
Mean · log ratio
Change in Tumor Size (CTS)
log ratioRamucirumab and EribulinEribulin Monotherapy
Change in Tumor Size (CTS)-0.20 ± 0.33-0.20 ± 0.28
SecondaryNumber of Participants With Anti-Ramucirumab Antibodies

The number of participants who developed treatment-emergent antibody responses after baseline. The antibody test can produce positive results in participants without ramucirumab exposure. Treatment emergent anti-ramucirumab antibody positive was defined as: when baseline titer was greater than 0 and post baseline titer was equal to or greater than 4-fold the baseline titer or if the baseline titer was not detected and post baseline titer is equal to or greater than a value of 20.

Time frame:
Day 1 of Cycle 1, Cycle 3, Cycle 5 and 30 days after last dose of study drug up to 17.7 months
Reported as:
Number · participants
Number of Participants With Anti-Ramucirumab Antibodies
participantsRamucirumab and EribulinEribulin Monotherapy
Number of Participants With Anti-Ramucirumab Antibodies42
Other pre-specifiedNumber of Participants With Adverse Events (AE) and Participants Who Died

Participants who died or who had clinically significant events defined as serious AEs (SAEs) and other non-serious AEs (regardless of causality). A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline up to end of treatment and within 30 days of last dose of study drug (22.6 months)
Reported as:
Number · participants
Number of Participants With Adverse Events (AE) and Participants Who Died
participantsRamucirumab and EribulinEribulin Monotherapy
SAE2612
Other non-SAE6865
Died3032

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab and Eribulin—26/69 (37.7%)67/69 (97.1%)
Eribulin Monotherapy—12/65 (18.5%)64/65 (98.5%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventRamucirumab and EribulinEribulin Monotherapy
NeutropeniaBlood and lymphatic system disorders4/691/65
Febrile neutropeniaBlood and lymphatic system disorders3/691/65
DehydrationMetabolism and nutrition disorders3/690/65
Abdominal painGastrointestinal disorders1/692/65
AscitesGastrointestinal disorders2/692/65
AnaemiaBlood and lymphatic system disorders2/690/65
PancreatitisGastrointestinal disorders2/690/65
StomatitisGastrointestinal disorders2/690/65
CellulitisInfections and infestations2/690/65
PneumoniaInfections and infestations2/690/65
Most frequent other events
Showing 10 of 67
Most frequent other events
EventRamucirumab and EribulinEribulin Monotherapy
FatigueGeneral disorders43/6938/65
NeutropeniaBlood and lymphatic system disorders27/6929/65
NauseaGastrointestinal disorders28/6927/65
HeadacheNervous system disorders27/6910/65
ConstipationGastrointestinal disorders20/6919/65
AlopeciaSkin and subcutaneous tissue disorders20/6915/65
VomitingGastrointestinal disorders19/6917/65
Decreased appetiteMetabolism and nutrition disorders19/6912/65
Peripheral sensory neuropathyNervous system disorders15/6917/65
DiarrhoeaGastrointestinal disorders17/6910/65

Baseline characteristics

All randomized participants

Age, Categorical
Age, Categorical(Participants)Ramucirumab and EribulinEribulin MonotherapyTotal
<=18 years000
Between 18 and 65 years6253115
>=65 years91726
Gender
Gender(Participants)Ramucirumab and EribulinEribulin MonotherapyTotal
Female7170141
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab and EribulinEribulin MonotherapyTotal
Hispanic or Latino538
Not Hispanic or Latino6567132
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ramucirumab and EribulinEribulin MonotherapyTotal
American Indian or Alaska Native011
Asian112
Black or African American11819
White5458112
Other527
Region of Enrollment
Region of Enrollment(participants)Ramucirumab and EribulinEribulin MonotherapyTotal
United States7170141
08

Study locations

52 sites
  • ImClone Investigational Site
    Birmingham, Alabama 35211, United States
  • ImClone Investigational Site
    Gilroy, California 95020, United States
  • ImClone Investigational Site
    Palm Springs, California 92262, United States
  • ImClone Investigational Site
    Denver, Colorado 80220, United States
  • ImClone Investigational Site
    Southington, Connecticut 06489, United States
  • ImClone Investigational Site
    Fort Myers, Florida 33916, United States
  • ImClone Investigational Site
    Jacksonville, Florida 32207, United States
  • ImClone Investigational Site
    Orlando, Florida 32806, United States
  • ImClone Investigational Site
    Plantation, Florida 33324, United States
  • ImClone Investigational Site
    Port St Lucie, Florida 34952, United States
  • ImClone Investigational Site
    St. Petersburg, Florida 33705, United States
  • ImClone Investigational Site
    Tampa, Florida 33612, United States
  • ImClone Investigational Site
    Albany, Georgia 31701, United States
  • ImClone Investigational Site
    Lawrenceville, Georgia 30046, United States
  • ImClone Investigational Site
    Park Ridge, Illinois 60068, United States
  • ImClone Investigational Site
    Columbia, Maryland 21044, United States
  • ImClone Investigational Site
    Rockville, Maryland 20850, United States
  • ImClone Investigational Site
    Dearborn, Michigan 48126, United States
  • ImClone Investigational Site
    Minneapolis, Minnesota 55404, United States
  • ImClone Investigational Site
    St Louis, Missouri 63110, United States
  • ImClone Investigational Site
    St. Joseph, Missouri 64507, United States
  • ImClone Investigational Site
    Henderson, Nevada 89074, United States
  • ImClone Investigational Site
    Morristown, New Jersey 07960, United States
  • ImClone Investigational Site
    Bronx, New York 10469, United States
  • ImClone Investigational Site
    Johnson City, New York 13790, United States
  • ImClone Investigational Site
    Lake Success, New York 11042, United States
  • ImClone Investigational Site
    Burlington, North Carolina 27215, United States
  • ImClone Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • ImClone Investigational Site
    Dayton, Ohio 45429, United States
  • ImClone Investigational Site
    Middletown, Ohio 45042, United States
  • ImClone Investigational Site
    Toledo, Ohio 43623, United States
  • ImClone Investigational Site
    Portland, Oregon 97213, United States
  • ImClone Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • ImClone Investigational Site
    Charleston, South Carolina 29414, United States
  • ImClone Investigational Site
    Greenville, South Carolina 29605, United States
  • ImClone Investigational Site
    Chattanooga, Tennessee 37404, United States
  • ImClone Investigational Site
    Nashville, Tennessee 37203, United States
  • ImClone Investigational Site
    Arlington, Texas 76014, United States
  • ImClone Investigational Site
    Bedford, Texas 76022, United States
  • ImClone Investigational Site
    Dallas, Texas 75246, United States
  • ImClone Investigational Site
    Fort Worth, Texas 76104, United States
  • ImClone Investigational Site
    Houston, Texas 77024, United States
  • ImClone Investigational Site
    Plano, Texas 75075, United States
  • ImClone Investigational Site
    San Antonio, Texas 78217, United States
  • ImClone Investigational Site
    The Woodlands, Texas 77380, United States
  • ImClone Investigational Site
    Tyler, Texas 75702, United States
  • ImClone Investigational Site
    Rutland, Vermont 05701, United States
  • ImClone Investigational Site
    Fairfax, Virginia 22031, United States
  • ImClone Investigational Site
    Norfolk, Virginia 23502, United States
  • ImClone Investigational Site
    Richmond, Virginia 23230, United States
  • ImClone Investigational Site
    Salem, Virginia 24153, United States
  • ImClone Investigational Site
    Vancouver, Washington 98684, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Sep 2013 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 11 months after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2011
First posted
Sep 2, 2011
Start
Nov 2011
Primary completionActual
Sep 2013
CompletionActual
Jun 2014
Results delay requested
Apr 25, 2014
Results first posted
Aug 19, 2014
Last update
Feb 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01427933
Responsible party
Sponsor
First posted
Sep 2, 2011
Start date
Nov 2011
Primary completion
Sep 2013
Completion
Jun 2014
Results posted
Aug 19, 2014
Last update
Feb 6, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion